-
BMC Med: "It's good to have a few more" evidence +1! 46% lower risk of endometrial cancer!
Time of Update: 2023-01-04
The results showed that in univariate MR analysis, in addition to the known risk factors BMI, age at menarche, and age at menopause, the researchers also found evidence of a causal effect of live births (inverse variance weighted (IVW) odds ratio (OR): 0.
-
Systemic immune landscape of cancer
Time of Update: 2023-01-04
Recent studies have shown that an effective response to preoperative neoadjuvant chemotherapy for triple-negative breast cancer (TNBC) induces the recruitment of new T cell clones to TME rather than the expansion of original cells.
-
Transl Res: Major advances in concomitant diagnostics with targeted drugs for lung cancer: a systematic assessment of the sensitivity of 74,389 rare EGFR mutations to 5 first-line targeted inhibitors
Time of Update: 2023-01-04
Enrichment of EGFR Sub-Del library mutants and EGFR Ins-1 library variants for the cytotoxicity of five TKIsIn summary, the sensitivity of relevant mutations to five first-line EGFR-TKI-targeted drugs was evaluated by systematic drug sensitivity screening experiments for 7,4389 rare variants of EGFR gene in lung cancer.
-
In the third year of Pink Bloom Day, Johnson & Johnson supported the Primary Insurance Foundation's call for scientific popularization of breast reconstruction concepts
Time of Update: 2023-01-04
Three years of pink bloom: breast reconstruction is becoming the choice of more and more patientsThis year is the third year that China Primary Health Care Foundation launched the "Pink Bloom Day", using the public welfare micro-film "Pink Letter" as the carrier, hoping to unite more industry experts, medical institutions, large health enterprises and other forces, so that more patients can feel companionship and support when fighting the disease, and encourage them to overcome difficulties and bloom bravely.
-
Workflow of TCR-T cell therapy
Time of Update: 2023-01-04
Preclinical safety testing is also necessary to ensure minimal off-target effects and cross-reactivity of isolated high-affinity TCRs. Viral vectors are commonly used to genetically modify autologous patient T cells to express validated therapeutic TCR before being transfused back into the patient.
-
Take you to the cancer target KRAS
Time of Update: 2023-01-04
： ， 。 ， ， prefaceOn May 28, 2021, the US FDA announced the accelerated approval of Lumakras (sotorasib, AMG510) developed by Amgen for the treatment of non-small cell lung cancer (NSCLC) with tumors carrying the KRAS G12C mutation Patients.
-
Lancet Oncology: mRNA cancer vaccines and their clinical progress
Time of Update: 2023-01-04
So, how many more steps do we need to take before these mRNA cancer vaccines can truly benefit cancer patients?03Hope and challengeAt present, several clinical trials have greatly promoted the research and development process of mRNA cancer vaccines, but they still face many challenges and problems.
-
J Clin Oncol: Zebrutinib versus irutinib for relapsed/refractory chronic lymphocytic leukemia
Time of Update: 2023-01-04
The ALPINE trial is a global, randomized, open-label, Phase 3 clinical study comparing the efficacy and safety of zebratinib with irutinib in patients with relapsed/refractory chronic lymphocytic leukemia.
-
European Radiology: Value of DWI in predicting response to novel adjuvant therapies for locally advanced rectal cancer
Time of Update: 2023-01-04
Recently, a study published in the journal European Radiology conducted a DWI analysis in LARC patients before TNT, and discussed the potential predictive value of DWI value in distinguishing between pCR and non-pCR patients, which provided a reference for improving the treatment effect and clinical prognosis of patients.
-
The founder of the company "One Drop of Blood for Cancer" was sentenced to 11 years!
Time of Update: 2023-01-04
Elizabeth Holmes, who founded the super unicorn company Theranos, once claimed to be able to quickly detect whether a person has cancer, diabetes and other diseases by collecting a few drops of blood from the fingertip, which is considered to have "set off a revolution in disease diagnosis".
-
Eur Urol Open Sci: Lower blood LRG1 levels predict patients at high risk of progression to castration-resistant prostate cancer
Time of Update: 2023-01-04
Recently, researchers from Norway published an article in Eur Urol Open Sci to evaluate the added value of blood LRG1 in predicting treatment failure in patients undergoing radical prostatectomy (RP).
-
European Radiology: Quantitative CT to assess the value of predicting prognosis in patients with locally advanced esophageal cancer
Time of Update: 2023-01-04
Body mass index, treatment strategy, thickness change ratio (ΔTHmax), CT value (ΔCTVaxial) and short diameter (ΔSD-LN) of the primary tumor, and enlarged small lymph nodes (ESLN) after two cycles of chemotherapy were identified as independent factors predicting overall survival (OS).
-
J Clin Oncol: Trametinib ±dabrafenib for the treatment of BRAF V600-mutant low-grade gliomas in children
Time of Update: 2023-01-04
Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600–Mutant Low-Grade Glioma.
Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600–Mutant Low-Grade Glioma.
-
NCCN Clinical Practice Guidelines: Lung Cancer Screening 2022.2 (Chinese)
Time of Update: 2023-01-04
It is recommended that medical institutions that perform lung cancer screening adopt a multidisciplinary collaborative approach including thoracic radiology, respiratory medicine, and surgical surgery.
Evaluation of suspected lung cancer requires a multidisciplinary team with expertise in the management of pulmonary nodules, including thoracic radiology, respiratory medicine, and thoracic surgery.
-
Patent Research Patent research report on ATM inhibitors in the field of synthetic lethality
Time of Update: 2023-01-04
Patented Research Report Series, launched by the Biomedical Department of Smart Buds, selects new targets and new mechanisms worthy of attention, and conducts detailed research and analysis around the target, including the elaboration of the mechanism of action, the patent layout of listed drugs and drugs under development and the detailed interpretation of key patents, etc.
-
European Radiology: MRI in the differentiation of benign and metastatic retropharyngeal lymph nodes
Time of Update: 2023-01-04
This study shows that synthetic MRI and DWI-derived quantitative parameters (T1, T2, PD, T1 SD, and ADC) have clinically important clinical value in distinguishing benign and metastatic RLN, and T1SD values have the highest diagnostic accuracy in distinguishing between the two entities.
-
European Radiology: The value of CT body composition quantification for the evaluation of lymphoma treatment in pediatrics, adolescents and young adults
Time of Update: 2023-01-04
Abdominal CT images of an 18-year-old male patient diagnosed with stage 1 non-Hodgkin lymphoma, and measurements (SAT, VAT, and SkM) for each BC region of interest changed significantly at treatment follow-up imaging time points when comparing (A) baseline to (B).
-
These 2 kinds of lung nodules are very easy to develop into lung cancer!
Time of Update: 2023-01-04
After reading this article, "lung nodules" and "lung cancer" are no longer stupid and unclear! Pulmonary nodules usually refer to circular, densely enhanced opacities ≤ 3 cm in diameter within the lun
-
The 24th round of Long March Difficult Tumor MTB Conference focused on the long-term benefits of precise diagnosis and treatment of MSS bowel cancer patients, and analyzed the characteristics, mechanism and treatment plan of rare EGFR19delins mutations
Time of Update: 2023-01-04
Patients with EGFR TKI-resistant advanced NSCLC may benefit from immunotherapy With the in-depth understanding of the immunomodulatory role of targeted drugs and the continuous generation of clinical evidence, immunotherapy is expected to bring new hope for driver-positive non-small cell lung cancer28.
-
Nature sub-journal: Wang Cun/Qin Wenxin et al. of Shanghai Jiao Tong University published a review of the latest clinical progress in the treatment of advanced liver cancer
Time of Update: 2023-01-04
Immunomodulatory effects of molecular targeted agents (Image from Nature Reviews Gastroenterology & Hepatology)Subsequently, more successful projects have been completed, leading to regulatory approvals for lenvatinib, cabozantinib and ramucirumab, as well as breakthrough combination therapies for atezolizumab + bevacizumab.
